MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 524422 | Name: BMS 180448

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMS 180448 is a prototype mitochondrial ATP-sensitive K+ (mitoK(ATP)) channel opener with cardioprotective and vasodilator properties. The cardioprotective effects of BMS-180448 against I/R heart injury may result from direct activation of mitoK(ATP) channel in cardiomyocytes. BMS-180426 is enantiomer with no antiischemic activity.

Chemical Structure

BMS 180448
BMS 180448
CAS#144264-47-1

Theoretical Analysis

MedKoo Cat#: 524422

Name: BMS 180448

CAS#: 144264-47-1

Chemical Formula: C20H18ClN5O2

Exact Mass: 395.1149

Molecular Weight: 395.84

Elemental Analysis: C, 60.68; H, 4.58; Cl, 8.96; N, 17.69; O, 8.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BMS 180448; BMS-180448; BMS180448;
IUPAC/Chemical Name
Guanidine, N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-, trans-
InChi Key
VLICJSLDCJXZBG-ZWKOTPCHSA-N
InChi Code
InChI=1S/C20H18ClN5O2/c1-20(2)18(27)17(15-9-12(10-22)3-8-16(15)28-20)26-19(24-11-23)25-14-6-4-13(21)5-7-14/h3-9,17-18,27H,1-2H3,(H2,24,25,26)/t17-,18+/m0/s1
SMILES Code
c12[C@@H]([C@H](C(Oc1ccc(C#N)c2)(C)C)O)\N=C(\NC#N)Nc1ccc(cc1)Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 395.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lee JH, Jung IS, Lee SH, Yang MK, Hwang JH, Lee HD, Cho YS, Song MJ, Yi KY, Yoo SE, Kwon SH, Kim B, Lee CS, Shin HS. Cardioprotective effects of BMS-180448, a prototype mitoK(ATP) channel opener, and the role of salvage kinases, in the rat model of global ischemia and reperfusion heart injury. Arch Pharm Res. 2007 May;30(5):634-40. PubMed PMID: 17615684. 2: Park YS, Yoo SE, Shin HS, Jin YR, Yun YP. Pharmacological characterization of vasorelaxant effects of BMS-180448, a novel cardioselective ATP-sensitive potassium channel opener, in rat aorta. J Pharmacol Sci. 2003 Jul;92(3):218-27. PubMed PMID: 12890887. 3: Weselcouch EO, Gomoll AW. Selectivity of BMS-180448 on myocardial versus brain blood flow in dogs and ferrets. J Cardiovasc Pharmacol. 1997 Jul;30(1):61-8. PubMed PMID: 9268222. 4: Gomoll AW, Roth RA, Swillo RE, Baird AJ, Sargent CS, Behling RW, Malone HJ, Grover GJ. Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448. J Pharmacol Exp Ther. 1997 Apr;281(1):24-33. PubMed PMID: 9103476. 5: Grover GJ, Sleph PG, Dzwonczyk S, Malone HJ, Behling RW. Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerations. J Cardiovasc Pharmacol. 1997 Jan;29(1):28-38. PubMed PMID: 9007667. 6: Lodge NJ, Smith MA. The novel cardioprotective agent BMS-180448 activates a potassium conductance in cardiac and vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):444-51. PubMed PMID: 8897447. 7: D'Alonzo AJ, Grover GJ, Darbenzio RB, Sewter JC, Hess TA, Dzwonczyk S, Sleph PG. Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts. Pharmacology. 1996 Feb;52(2):101-12. PubMed PMID: 8851631. 8: Grover GJ, Parham CS, Whigan DB, Mitroka JG. BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs. J Pharmacol Exp Ther. 1996 Feb;276(2):380-7. PubMed PMID: 8632300. 9: Monticello TM, Sargent CA, McGill JR, Barton DS, Grover GJ. Amelioration of ischemia/reperfusion injury in isolated rats hearts by the ATP-sensitive potassium channel opener BMS-180448. Cardiovasc Res. 1996 Jan;31(1):93-101. PubMed PMID: 8849593. 10: D'Alonzo AJ, Darbenzio RB, Sewter JC, Hess TA, Grover GJ, Sleph PG, Normandin DE, Lodge NJ. A comparison between the effects of BMS-180448, a novel K+ channel opener, and cromakalim in rat and dog. Eur J Pharmacol. 1995 Dec 27;294(1):271-80. PubMed PMID: 8788441. 11: Grover GJ, D'Alonzo AJ, Hess T, Sleph PG, Darbenzio RB. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening. Cardiovasc Res. 1995 Nov;30(5):731-8. PubMed PMID: 8595620. 12: Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol. 1995 Jan;25(1):40-50. PubMed PMID: 7723352.